Korro Bio receives Australian clearance to begin Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro Bio, Inc.

Australian HREC approval and TGA clearance obtained for Phase 1/2a REWRITE study of KRRO-110 in AATD.
First participant dosing expected Q1 2025; interim readout H2 2025; study completion anticipated 2026.
KRRO-110 aims to edit RNA to produce functional M-AAT; in mouse model, >60% editing achieved at therapeutically relevant levels.
Study will evaluate safety, tolerability, PK/PD of single and multiple ascending doses in PiZZ genotype patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.